Farxiga Cost in Tennessee 2026: Cash Price, Medicaid, and Compounded Options

What Is Farxiga and Why Does It Cost So Much?

Farxiga is AstraZeneca's brand-name tablet containing dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor. The drug blocks glucose reabsorption in the kidney's proximal tubule, driving excess sugar out through urine and reducing blood glucose without stimulating insulin secretion directly [1]. AstraZeneca lists the wholesale acquisition cost at roughly $620 per 30-day supply in 2026, a price common to brand-name SGLT2 inhibitors that lack a fully interchangeable generic in the U.S. market.

Generic dapagliflozin has not received FDA approval as of mid-2025 under the standard Paragraph IV pathway, which means Tennessee patients cannot simply swap to a cheaper generic at a local pharmacy the way they can with metformin or lisinopril [2]. That patent exclusivity is the primary cost driver.

The three FDA-approved indications are type 2 diabetes (glycemic control), heart failure with reduced or preserved ejection fraction, and chronic kidney disease with or without diabetes [3]. Each indication was supported by a separate outcomes trial, and coverage decisions by Tennessee insurers follow that indication-specific evidence closely. This matters because TennCare's formulary decisions hinge on which indication a prescriber documents, not simply the drug name.

Farxiga Retail Price at Tennessee Pharmacies in 2026

Cash-pay prices at major Tennessee pharmacy chains vary by only a narrow margin. Expect $605 to $630 for a 30-tablet supply of dapagliflozin 10 mg at Walgreens, CVS, Kroger, and Publix locations across Memphis, Nashville, Knoxville, and Chattanooga. The 5 mg tablet used for type 2 diabetes in renally impaired patients carries nearly the same price, as AstraZeneca does not tier pricing by dose strength.

GoodRx and similar discount aggregators typically show prices in the $540 to $580 range when a coupon is applied at independent Tennessee pharmacies, though these coupons cannot be combined with insurance or government benefit programs such as TennCare [4]. Patients who are uninsured or whose plan does not cover Farxiga will find the GoodRx coupon is the simplest immediate discount.

The FDA approved Farxiga for heart failure in May 2020 after the DAPA-HF trial (N=4,744) demonstrated a 26% relative risk reduction in the composite of worsening heart failure or cardiovascular death compared with placebo (hazard ratio 0.74; 95% CI 0.65 to 0.85; P<0.001) [5]. That cardiovascular evidence strengthened payer interest in covering the drug for heart failure while leaving type 2 diabetes coverage decisions more contested on cost-effectiveness grounds.

TennCare (Tennessee Medicaid) Coverage for Farxiga

TennCare does not cover Farxiga for type 2 diabetes as a standalone indication. The formulary places dapagliflozin in a non-preferred or non-covered tier for T2D, reflecting Tennessee's preference for lower-cost agents including metformin, sulfonylureas, and SGLT2 competitors with different contract pricing.

Coverage is available with prior authorization for heart failure and for chronic kidney disease meeting specific eGFR criteria. The DAPA-CKD trial (N=4,304) showed dapagliflozin reduced a composite kidney and cardiovascular outcome by 39% relative to placebo in patients with CKD stages 2 through 4, including patients without diabetes (hazard ratio 0.61; 95% CI 0.51 to 0.72; P<0.001) [6]. That data drove CMS coverage decisions that cascaded into state Medicaid programs, including TennCare.

To obtain a prior authorization for heart failure or CKD under TennCare, a prescriber must document:

• A confirmed diagnosis of heart failure with reduced ejection fraction (ejection fraction <40%) or CKD with urinary albumin-to-creatinine ratio above 200 mg/g
• Intolerance to or contraindications for ACE inhibitors or ARBs, or concurrent use
• Recent lab values confirming eGFR above the prescribing threshold (eGFR ≥25 mL/min/1.73 m² for CKD indication)

Denials based on T2D-only documentation are common. Patients whose providers resubmit with an explicit heart failure or CKD diagnosis often succeed on appeal [7].

Commercial Insurance Coverage in Tennessee

Most major commercial plans sold on Tennessee's ACA marketplace and through large employers cover Farxiga, though tier placement varies. Blue Cross Blue Shield of Tennessee, Cigna, Aetna, and UnitedHealthcare Tennessee plans typically place dapagliflozin on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), yielding a co-pay of $50 to $150 per 30-day supply after deductible [8].

The American Diabetes Association's 2024 Standards of Care recommend SGLT2 inhibitors for patients with type 2 diabetes and established cardiovascular disease, heart failure, or CKD, describing them as agents that "reduce cardiovascular and renal risk independent of glycemic control" [9]. That guideline language has increased medical necessity arguments for coverage, and many Tennessee insurers have responded by broadening formulary access.

Step therapy is still required by several plans, meaning the insurer may require documented failure of at least one first-line agent (commonly metformin) before approving dapagliflozin. Exceptions are typically granted when metformin is contraindicated due to eGFR below 30 or gastrointestinal intolerance.

Employer self-funded plans operating under ERISA are regulated federally, not by Tennessee state insurance rules, so their formularies can differ significantly even when administered by Tennessee-based insurers. Employees should request a formulary search from their HR benefits portal or call the plan's pharmacy benefit manager directly.

AstraZeneca Savings Card: How It Works in Tennessee

AstraZeneca's AZ&Me and Farxiga savings card programs reduce out-of-pocket costs for commercially insured patients who meet income and enrollment criteria. Eligible patients may pay as little as $0 per month for a 30-day supply [10].

The savings card does not work for patients on TennCare, Medicare, Medicaid, or any other government-funded program. Federal anti-kickback rules prohibit drug manufacturer co-pay assistance for federally reimbursed prescriptions. Attempting to use the card while enrolled in TennCare is a compliance violation.

For commercially insured Tennesseans who do not qualify for government coverage, the application process takes about five minutes online at AstraZeneca's patient assistance portal. A prescriber NPI number and insurance card information are required. The card is typically activated within 24 to 48 hours and can be presented at any participating Tennessee retail pharmacy. Income-based assistance programs (AZ&Me for uninsured patients) may provide Farxiga at no cost to patients below 600% of the federal poverty level.

Compounded Dapagliflozin in Tennessee: What the Law Says

Licensed 503A compounding pharmacies in Tennessee may legally prepare dapagliflozin compounds for individual patients with a valid prescription. The 503A designation under the Federal Food, Drug, and Cosmetic Act permits patient-specific compounding when a commercially available product does not meet the patient's clinical needs [11].

Compounded dapagliflozin is not AB-rated as a generic equivalent to Farxiga. It cannot be automatically substituted at the pharmacy counter and requires a prescription explicitly for the compounded formulation. The Tennessee Board of Pharmacy oversees 503A pharmacies operating within state lines and enforces USP Chapter 795 standards for non-sterile compounding [12].

Cost is the most common clinical justification cited by prescribers. Some Tennessee 503A pharmacies offer dapagliflozin capsules or oral solutions at substantially lower monthly costs than the brand-name tablet, with some providers structuring pricing that makes the drug accessible to uninsured patients. Specific pricing varies by pharmacy and formulation.

Patients should be aware that compounded preparations have not undergone the same FDA bioavailability and bioequivalence testing as the brand-name product. A prescriber must document a specific patient need. Prescribers at HealthRX perform this assessment during the clinical intake before routing any compounded dapagliflozin prescription.

The following framework summarizes how a HealthRX clinical provider evaluates a Tennessee patient's dapagliflozin access pathway during intake:

HealthRX Tennessee Dapagliflozin Access Decision Framework

1. Confirm indication: T2D only, HF, or CKD. This determines TennCare eligibility.
2. Check insurance tier: If commercially insured, apply AstraZeneca savings card. Target co-pay: $0 to $35/month.
3. Screen for government program enrollment: If TennCare or Medicare, savings card is ineligible.
4. Document prior authorization need: For TennCare HF or CKD, prepare PA with diagnosis codes, eGFR, and echocardiogram data.
5. Evaluate compounding appropriateness: If uninsured or T2D-only on TennCare, review 503A pharmacy options and document clinical rationale.
6. Set follow-up: eGFR recheck at 4 weeks after initiation; HbA1c at 12 weeks.

Telehealth Prescribing of Farxiga in Tennessee

Tennessee permits telehealth prescribing for non-controlled prescription medications, and dapagliflozin qualifies. A licensed Tennessee prescriber can evaluate a patient via audio-video telehealth, document a valid patient-provider relationship, and transmit a Farxiga or dapagliflozin prescription electronically to a Tennessee pharmacy or mail-order pharmacy serving Tennessee residents [13].

The Tennessee Medical Practice Act requires that a telehealth prescriber hold a Tennessee license or be licensed in a state with a compact agreement covering Tennessee. As of 2025, Tennessee participates in the Interstate Medical Licensure Compact, broadening the pool of telehealth providers who may legally prescribe to Tennessee patients [14].

HealthRX providers are licensed to prescribe in Tennessee. An intake visit covering cardiovascular history, renal function review, and current medication reconciliation typically runs 20 to 30 minutes. Lab work ordered through the platform can be completed at a Tennessee draw site before the prescription is issued, satisfying standard-of-care requirements for baseline eGFR and HbA1c.

Dapagliflozin Dosing and Clinical Monitoring in Tennessee Patients

The FDA-approved starting dose for type 2 diabetes is 5 mg once daily, with titration to 10 mg if tolerated and additional glycemic lowering is needed [3]. For heart failure and CKD, 10 mg once daily is the recommended dose from the start, matching the DAPA-HF and DAPA-CKD trial protocols.

Prescribers must check eGFR before initiating therapy. Dapagliflozin is not recommended for glycemic control when eGFR falls below 45 mL/min/1.73 m², though it retains its cardiorenal protective mechanism and FDA labeling supports use for heart failure and CKD at eGFR as low as 25 mL/min/1.73 m² [3]. Patients with recurrent urinary tract infections, genital mycotic infections, or volume depletion warrant closer monitoring during the first 90 days.

The DECLARE-TIMI 58 trial (N=17,160) demonstrated dapagliflozin significantly reduced the risk of hospitalization for heart failure or cardiovascular death in patients with type 2 diabetes and either established cardiovascular disease or multiple risk factors (hazard ratio 0.83; 95% CI 0.73 to 0.95; P=0.005 for heart failure hospitalization) [15]. That broad population overlaps substantially with Tennessee's high-prevalence cardiovascular disease burden, making dapagliflozin a clinically relevant option for many patients across the state.

Blood pressure, body weight, and renal function should be rechecked at four weeks post-initiation. Modest reductions of 2 to 3 mmHg systolic blood pressure and 2 to 4 kg body weight are typical in the first 12 weeks and represent pharmacodynamic effects rather than adverse events [16].

What Farxiga Actually Costs Compared to Similar Drugs in Tennessee

Comparing SGLT2 inhibitors on a cash-pay basis in Tennessee reveals meaningful price differences:

• Jardiance (empagliflozin 10 mg, 30 tablets): approximately $620 to $640 per month
• Invokana (canagliflozin 100 mg, 30 tablets): approximately $590 to $620 per month
• Farxiga (dapagliflozin 10 mg, 30 tablets): approximately $605 to $630 per month

All three carry similar list prices. The class as a whole lacks a widely available generic in the U.S. as of 2025, leaving cash-pay patients facing comparable out-of-pocket burdens across agents [17]. Class-level cardiovascular and renal outcomes data are now available for all three, and the 2023 ACC/AHA Heart Failure Guidelines state that SGLT2 inhibitors are recommended for patients with HFrEF to reduce hospitalizations and mortality, with a Class I, Level A recommendation [18].

Switching between SGLT2 inhibitors for cost reasons requires a new prescription and a prescriber's clinical review, as the agents are not interchangeable on the pharmacy level. If a Tennessee insurer covers Jardiance but not Farxiga, a prescriber can write for empagliflozin instead with essentially equivalent cardiorenal outcomes data.

Applying for Patient Assistance Programs in Tennessee

AstraZeneca operates two programs relevant to Tennessee patients without commercial insurance:

AZ&Me Prescription Savings Program. Available to uninsured or underinsured patients with household income at or below 600% of the federal poverty level. The program provides Farxiga at no cost, shipped directly to the patient or their pharmacy. The application requires income verification and is renewed annually [10].

Farxiga Together Savings Program. A co-pay card program for commercially insured patients. Accepted at retail pharmacies statewide. Government program beneficiaries are excluded.

The NeedyMeds and RxAssist databases list additional Tennessee-specific assistance options and local charitable pharmacy programs in Memphis, Nashville, and Knoxville that may provide bridge supplies during insurance gap periods [19]. Tennessee's Prescription Assistance Program (PAP) through the Tennessee Department of Health coordinates enrollment for low-income state residents who meet federal non-duplication criteria.

How Tennessee's High CKD and Heart Failure Rates Affect Farxiga Coverage Decisions

Tennessee ranks among the top 10 U.S. states for chronic kidney disease prevalence, with the CDC reporting CKD affecting approximately 15% of Tennessee adults, higher than the national average of 14% [20]. Heart failure hospitalizations in Tennessee exceed the national rate, particularly in rural west Tennessee counties where access to cardiologists is limited.

These epidemiological facts mean a disproportionate share of Tennessee Farxiga candidates qualify under the HF or CKD indications rather than T2D alone. That matters because TennCare's coverage gap applies specifically to T2D. A patient presenting with both type 2 diabetes and CKD stage 3 has a viable path to TennCare coverage that a T2D-only patient does not.

Prescribers serving Tennessee patients should document all comorbid conditions explicitly in the prior authorization request. An eGFR of 42 mL/min/1.73 m² combined with a UACR of 350 mg/g satisfies the DAPA-CKD enrollment criteria and the TennCare PA criteria simultaneously [6]. Providers who document only "diabetes management" as the indication will face denial and need to resubmit.

The Kidney Disease: Improving Global Outcomes (KDIGO) 2022 guidelines state that "SGLT2 inhibitors are recommended for patients with type 2 diabetes and CKD who are at risk of CKD progression or cardiovascular events" and extend that recommendation to patients with CKD and heart failure regardless of diabetes status [21]. Referencing that guideline in a prior authorization letter strengthens the clinical argument for TennCare approval.

Filling a Farxiga Prescription Through Mail Order in Tennessee

Tennessee residents with commercial insurance may access 90-day mail-order supplies through pharmacy benefit managers including Express Scripts, CVS Caremark, and OptumRx. A 90-day supply through mail order typically costs two co-pays rather than three, saving $50 to $150 for patients on Tier 3 plans.

Mail-order pharmacies must be licensed to dispense to Tennessee addresses. Specialty and compounding pharmacies shipping into Tennessee must hold a valid Tennessee Board of Pharmacy non-resident pharmacy permit [12]. Patients ordering from any online source should verify that permit status before providing payment information.

Telehealth platforms including HealthRX can route e-prescriptions to a patient's preferred Tennessee pharmacy or to a contracted mail-order pharmacy. The 90-day supply option is available for any stable patient who has completed the initial titration period without tolerability issues.

Check your plan's formulary annually during open enrollment. Several Tennessee Blue Cross Blue Shield plans restructured their SGLT2 inhibitor tier placements for 2025 plan years, and those changes carry into 2026 plan year renewal cycles. A drug that was covered at Tier 3 in 2024 may have shifted to Tier 4 or added a step therapy requirement for the new plan year.

A confirmed eGFR above 25 mL/min/1.73 m², documented at your most recent lab draw, is the single fastest way to keep a Farxiga prior authorization approval on file with TennCare.